Esperion Therapeutics Stock Probability of Future Stock Price Finishing Over 7.06
| ESPR Stock | USD 2.52 0.05 2.02% |
Esperion |
Esperion Therapeutics Target Price Odds to finish over 7.06
The tendency of Esperion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 7.06 or more in 90 days |
| 2.52 | 90 days | 7.06 | close to zero percent |
Based on a normal probability distribution, the odds of Esperion Therapeutics to move over $ 7.06 or more in 90 days from now is close to zero percent (This Esperion Therapeutics probability density function shows the probability of Esperion Stock to fall within a particular range of prices over 90 days) . Probability of Esperion Therapeutics price to stay between its current price of $ 2.52 and $ 7.06 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days Esperion Therapeutics has a beta of 0.0154 suggesting as returns on the market go up, Esperion Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Esperion Therapeutics will be expected to be much smaller as well. Additionally Esperion Therapeutics has an alpha of 0.5498, implying that it can generate a 0.55 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Esperion Therapeutics Price Density |
| Price |
Predictive Modules for Esperion Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Esperion Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Esperion Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Esperion Therapeutics is not an exception. The market had few large corrections towards the Esperion Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Esperion Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Esperion Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.55 | |
β | Beta against Dow Jones | 0.02 | |
σ | Overall volatility | 0.23 | |
Ir | Information ratio | 0.1 |
Esperion Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Esperion Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Esperion Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Esperion Therapeutics appears to be risky and price may revert if volatility continues | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with loss before overhead, payroll, taxes, and interest of (70.42 M). | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 |
Esperion Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Esperion Stock often depends not only on the future outlook of the current and potential Esperion Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Esperion Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 103.1 M | |
| Cash And Short Term Investments | 82.2 M |
Esperion Therapeutics Technical Analysis
Esperion Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Esperion Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Esperion Therapeutics. In general, you should focus on analyzing Esperion Stock price patterns and their correlations with different microeconomic environments and drivers.
Esperion Therapeutics Predictive Forecast Models
Esperion Therapeutics' time-series forecasting models is one of many Esperion Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Esperion Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Esperion Therapeutics
Checking the ongoing alerts about Esperion Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Esperion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Esperion Therapeutics appears to be risky and price may revert if volatility continues | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with loss before overhead, payroll, taxes, and interest of (70.42 M). | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.